+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Improving the Therapeutic Ratio in Head and Neck Cancer, Vol 6. Cancer Sensitizing Agents for Chemotherapy

  • ID: 4806680
  • Book
  • 376 Pages
  • Elsevier Science and Technology
1 of 2

Improving the Therapeutic Ratio in Head and Neck Cancer provides a complete review of current approaches to modulating therapeutic sensitivity in head and neck cancer. It presents a broad background of current approaches and by highlighting the potential for clinical translational, introduces a roadmap for how to move promising preclinical findings into the clinic.

The book discusses topics such as immunotherapy and molecularly targeted therapies in head and neck cancer, PI3k/mTOR pathway, autophagy inhibition to sensitize HNC to radiation and chemotherapy, TAM and Eph/Ephrin family proteins and metabolic reprogramming to modulate therapeutic sensitivity. Additionally, it details approaches to improve the response to immunotherapy, and Chk1/2 inhibition in radiation and cetuximab resistance.

This book is a valuable source to head and neck cancer researchers and advanced students, and to those studying specific approaches in other model systems and disease sites.

  • Provides key scientific background for clinicians when developing novel clinical trials and important examples for basic scientists of the types of work required to move a concept from the lab to the clinic
  • Presents consistent pathway diagrams in each chapter, thus making it easier to understand complicated pathways
  • Includes chapter summaries of the critical next steps needed to move studies from their current state into practice changing clinical data

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 2

1. Overview of head and neck cancer management 2. The role of immunotherapy and molecularly targeted therapies in head and neck cancer 3. Targeting the PI3K/mTOR pathway 4. Autophagy inhibition to sensitize HNC to radiation and chemotherapy 5. Overcoming head and neck cancer stem cells 6. TAM Family proteins and therapy resistance 7. Eph/Ephrin family proteins and theapy resistance 8. Metabolic reprogramming to modulate therapeutic sensitivity 9. FGFR and cMET 10. Targeting GPCRs in HNC 11. Improving the response to immunotherapy 12. Chk1/2 inhibition in radiation and cetuximab resistance

Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll